BCR and diffuse large B-cell lymphoma: Consistent with the chronic activation of BCR signaling selectively in the ABC DLBCL subtype, ABC DLBCL patients responded significantly better to this BCR signaling inhibitor in comparison to patients with the GCB DLBCL subtype (Wilson et al., 2015).